Mark P. Rubinstein
Impact in
- Immunology top 0.5%
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- Immune cells in cancer
- Oncology top 1%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
Papers in
- Immunology 58
- Immune Cell Function and Interaction 41
- Immunotherapy and Immune Responses 34
- T-cell and B-cell Immunology 27
- Oncology 45
- CAR-T cell therapy research 33
- Cancer Immunotherapy and Biomarkers 20
- Co-authors
- Charles D. SurhJonathan SprentOnur BoymanMarek KovářAnanda W. GoldrathDavid J. ColeJared F. PurtonZihai Li
- Journals
- The Journal of Immunology (7 papers)Cancer Research (5 papers)Journal of Clinical Oncology (4 papers)Journal for ImmunoTherapy of Cancer (4 papers)Frontiers in Immunology (3 papers)
- Partner nations
- United StatesEgyptAustralia
In The Last Decade
Mark P. Rubinstein
75 papers receiving 4.5k citations
Hit Papers
Peers
Comparison fields: 5 of 110
- Immunology 3.4k
- Oncology 2.1k
- Cancer Research 339
- Hematology 190
- Virology 68
Countries citing papers authored by Mark P. Rubinstein
This map shows the geographic impact of Mark P. Rubinstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark P. Rubinstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark P. Rubinstein more than expected).
Fields of papers citing papers by Mark P. Rubinstein
This network shows the impact of papers produced by Mark P. Rubinstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark P. Rubinstein. The network helps show where Mark P. Rubinstein may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mark P. Rubinstein, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 18 | |
| 4 | 2024 | 5 | |
| 5 | 2022 | 12 | |
| 6 | 2021 | 5 | |
| 7 | 2020 | 31 | |
| 8 | 2020 | 91 | |
| 9 | Identification of human CD4+ T cell populations with distinct antitumor activity | 2020 | 1 |
| 10 | 2019 | 51 | |
| 11 | 2018 | 7 | |
| 12 | 2017 | 265 | |
| 13 | 2016 | 24 | |
| 14 | 2015 | 21 | |
| 15 | 2015 | 23 | |
| 16 | 2013 | 157 | |
| 17 | Macrophage Expression of Hypoxia-Inducible Factor-1α Suppresses T-Cell Function and Promotes Tumor Progression Hit paper breakdown → | 2010 | 523 |
| 18 | 2008 | 140 | |
| 19 | Selective Stimulation of T Cell Subsets with Antibody-Cytokine Immune Complexes Hit paper breakdown → | 2006 | 719 |
| 20 | 2006 | 47 |
About Mark P. Rubinstein
Mark P. Rubinstein is a scholar working on Immunology, Oncology, Physiology, Hematology and Internal Medicine, having authored 76 papers that have together received 4.6k indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (41 papers), Immunotherapy and Immune Responses (34 papers), CAR-T cell therapy research (33 papers), T-cell and B-cell Immunology (27 papers), Cancer Immunotherapy and Biomarkers (20 papers), Virus-based gene therapy research (4 papers), SARS-CoV-2 and COVID-19 Research (3 papers) and COVID-19 Clinical Research Studies (3 papers). The work is most often cited by research in Immunology (3.4k citations), Oncology (2.1k citations), Cancer Research (339 citations), Hematology (190 citations) and Virology (68 citations). Mark P. Rubinstein has collaborated with scholars based in United States, Egypt and Australia. Frequent co-authors include Charles D. Surh, Jonathan Sprent, Onur Boyman, Marek Kovář, Ananda W. Goldrath, David J. Cole, Jared F. Purton, Zihai Li, Chrystal M. Paulos and Mohamed L. Salem. Their work appears in journals such as The Journal of Immunology, Cancer Research, Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer and Frontiers in Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.